TNFRSF11A and prostate carcinoma: Luo et al.5 proposed that RANKL from tumor-infiltrating inflammatory cells activated RANK on prostate cancer and led to nuclear inhibitor of nuclear factor kappa-B (NF-κB) kinase subunit alpha (IKKα) activation to control cancer metastasis.